zepbound eli lilly - Search News

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Seeking Alpha · 1d

Eli Lilly Stock's Correction Brings Opportunity

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

MarketBeat on MSN · 2d

What Does the Future Hold for Eli Lilly?

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely the hottest medical sector story in 2024. With its offering of tirzepatide (branded as Mounjaro and Zepbound),

Investopedia on MSN20d

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

FiercePharma3d

Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Eli Lilly: Market Overreacted

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Forbes28d

Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

16d

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results